공시 • Apr 25
BIOQUAL Announces Retirement of Mike O'Flaherty from Board, Effective May 1, 2025 BIOQUAL, Inc. announced that Mr. Michael P. O’Flaherty will retire from his role as a BIOQUAL Board Member effective May 1, 2025. Mr. O’Flaherty served as the Chief Operating Officer and Secretary of the Corporation until he retired in 2015 at which time he was elected to the BIOQUAL Board. Mr. O’Flaherty is 86 years old and has served as a Director since 2015. His retirement is not connected to any disagreements with the Board’s policies or practices. 공시 • Jan 15
BIOQUAL, Inc. Announces Changes to Board of Directors BIOQUAL, Inc. announced that Mr. Charles Francisco retired from his role as a BIOQUAL Board Member effective December 31, 2024. Mr. Francisco is 85 years old and has served as a director since 1992. His retirement is not connected to any disagreements with the Board’s policies or practices. Additionally, on December 31, 2024, BIOQUAL appointed Ms. Amy Johnston to the BIOQUAL Board of Directors. Ms. Johnston will replace Mr. Francisco on the Board, thus, the number of directors will not change. Ms. Johnston has been working with and managing companies in the healthcare and biotech industries for over thirty years. She holds a Bachelor of Arts in Government and English (dual degree) and a Master of Arts degree in Secondary English Education from the College of William and Mary in Virginia. Among her career accomplishments: Led cross-functional teams to build commercial biotech teams and strategies while ensuring compliance with FDA regulations, Provided critical support in pre-launch and post-launch efforts for a Hepatitis C compound, achieving $1B in sales in the first year on the commercial market, Collaborated with media and advertising agencies, managed market teams, Key Opinion Leaders, and patient advocacy groups to educate both the medical community and the patients, By revising the strategy and operating model of a design/build employee-owned utility company, Amy and her business partner increased revenue from $10 million to $25 million even during the economically unstable period of the pandemic. Amy led the team that successfully valued and negotiated the sale of her interest in the company in 2022. 공시 • Oct 01
Bioqual, Inc. Declares Dividend, Payable on October 28, 2024 Bioqual, Inc.’s board of directors has declared a dividend of $0.50 per share for shareholders of record on October 7, 2024, payable on October 28, 2024. 공시 • Sep 15
Bioqual, Inc. Announces Reduction in Workforce BIOQUAL, Inc. announced a reduction in workforce (RIF) of approximately 10% of its employees effective September 9, 2024. The RIF was a necessary cost-cutting measure due to the decrease in revenue and profitability that BIOQUAL has experienced in the last year. In a post-COVID-19 environment, the Company has seen a significant drop in the demand for their services due to the development of COVID-19 vaccines and therapeutics and needed to realign its cost structure accordingly. BIOQUAL does not expect the RIF to impact the current services it provides or to hamper its business prospects for the future. 공시 • Oct 06
Bioqual, Inc. Appoints Charles (Chris) C. Kirk, Jr., CPA as Chief Financial Officer BIOQUAL, Inc. announced promotion of Mr. Charles (Chris) C. Kirk, Jr., CPA. to the position of chief financial officer. Mr. Kirk has over 25 years of experience in leadership roles in finance and accounting departments for both Government contracting and services-oriented companies as well as in the public accounting sector. Mr. Kirk has served as Director of Finance and Accounting for the company over the past year and has a degree in Accounting/Finance from the University of Maryland. In his role as Chief Financial Officer, Mr. Kirk will lead the Accounting/Finance team at BIOQUAL and will join the company's executive leadership team. 공시 • Sep 28
BIOQUAL Declares Dividend, Payable on October 27, 2022 BIOQUAL announced that its Board of Directors has declared a dividend of $1.00 per share for shareholders of record on October 6, 2022, payable on October 27, 2022. 공시 • Sep 22
Bioqual, Inc. Announces Publication of an Investigational COVID-19 Vaccine Candidate Bioqual, Inc. announced that Beth Israel Deaconess Medical Center immunologist Dan H. Barouch and colleagues, including members of the staff at BIOQUAL, showed in recently published previous work that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19. In new research published September 3, 2020 in Nature Medicine, Barouch and colleagues demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. The vaccine — developed through a collaboration between BIDMC and Janssen Pharmaceutical Companies of Johnson & Johnson — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. Ad26.COV2.S is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans. In July 2020, investigators at Janssen, Beth Israel Deaconess Medical Center, and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Pending clinical trial out-comes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants in September 2020. 
